Paper Details

  1. Home
  2. Paper Details

Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.

Author: CarusoV, CenderelloG, CopettiM, ForniG, GamberiniR, GangaR, MangiaA, PiazzollaV, PigaA, QuartaA, SantoroR, SarliR

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study examines the high rate of hepatitis C virus (HCV) infection in patients with thalassemia major, which is caused by contaminated blood transfusions. Patients with HCV infection have a higher risk of developing liver cancer. The side effects of the traditional treatment with Peg-IFN and Ribavirin have limited its use.
Paper Details　
Original Abstract of the Article :
Patients with thalassaemia major depend on blood transfusions. In Italy, up to 80% of thalassaemia patients bear HCV antibodies due to HCV contaminated transfusions before 1990. Thalassaemia patients with HCV infection have high risk of developing HCC. Treatment based on Pegylated-IFN (Peg-IFN) and ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/apt.14197

データ提供：米国国立医学図書館（NLM）

A Beacon of Hope for Thalassaemia Patients with HCV Infection

The field of hematology is constantly seeking new treatments for complex diseases, particularly those with high rates of complications. This randomized clinical trial focuses on patients with thalassaemia major, a blood disorder that requires regular blood transfusions. The study investigated the efficacy of a combination of sofosbuvir and ledipasvir in treating hepatitis C virus (HCV) infection in these patients. The results demonstrate a promising treatment option with high cure rates and reduced side effects compared to traditional treatments. It's like finding a refreshing oasis in the vast desert of hematological research, offering a haven of hope for patients facing a challenging diagnosis.

A New Dawn for Thalassaemia Patients

The study showed that sofosbuvir and ledipasvir were highly effective in eliminating HCV infection in thalassaemia patients. This is like discovering a hidden spring in the heart of a dry desert, offering a source of life-giving hydration for those in need. The treatment achieved high cure rates and was well-tolerated, offering a significant improvement over previous treatments. This is like building a sturdy oasis in the challenging landscape of thalassaemia management, providing a safe haven for patients to thrive.

Navigating the Desert of Chronic Illness

The findings suggest that sofosbuvir and ledipasvir represent a significant advancement in the treatment of HCV infection in thalassaemia patients. This is like finding a reliable camel caravan to navigate the challenges of chronic illness. The treatment's high efficacy and low side effects offer a brighter outlook for these patients, allowing them to focus on managing their thalassaemia and improving their overall quality of life.

Dr.Camel's Conclusion

This study provides a beacon of hope for thalassaemia patients with HCV infection, showcasing the effectiveness of sofosbuvir and ledipasvir in achieving high cure rates with minimal side effects. It's like finding a refreshing oasis in the vast desert of hematological research, offering a haven of hope and better health outcomes for these patients.

Date :
  1. Date Completed 2017-12-07
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

28660640

DOI: Digital Object Identifier

10.1111/apt.14197

Related Literature

Article Analysis
・Side Effects of ledipasvir and sofosbuvir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.